Victor Tsun Ho Yuen
Victor Tsun Ho Yuen has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Ahmad Aloufi
The University of British Columbia
1 shared publication- Calvin Ka-Fung Lo
The University of British Columbia
1 shared publication David R. Goodlett
Department of Biochemistry and Microbiology
1 shared publicationGeneviève Amaral
The University of British Columbia
1 shared publication- Hasan Hamze
Department of Pathology and Laboratory Medicine The University of British Columbia 2211 Wesbrook Mall, Vancouver, BC V6T 1Z7, Canada
1 shared publication Jennifer M. Grant
BC Centre for Disease Control
1 shared publication
Latest Publications
- Open Access
- 29 October 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e355
Reducing carbapenem use for low-risk AmpC-producing Enterobacterales: impact of a microbiology comment-based stewardship initiative
Background: AmpC B-lactamases cause resistance to broad-spectrum B-lactams with variable expression dependent on bacterial species. Practice remains heterogenous regarding treatment of infections caused by AmpC organisms. This study aimed to assess the impact of a microbiology comment-based stewardship intervention on the definitive treatment of low-risk AmpC-producing Enterobacterales bacteremia. Methods: This was a pre- and posttest quality improvement study conducted at Island Health Authority. A stewardship intervention involving amendment of a microbiology report comment regarding inducible resistance was implemented on February 13, 2023. Patients aged 18 and older with blood cultures growing low-risk AmpC-producing organisms were included. The primary end point of proportion of patients receiving ceftriaxone or piperacillin-tazobactam was compared between pre- (June 2021 to February 2023) and postintervention periods (February 2023 to October 2024). Secondary end points included clinical outcomes, ceftriaxone/piperacilin-tazobactam resistance rates, and C. difficile infection. Results: A total of 56 patients were included (25 preintervention and 31 postintervention). Definitive ceftriaxone/pipercillin-tazobactam antibiotic therapy was prescribed more frequently postintervention compared to preintervention (45.8% vs 5.0%, P < .001). After adjusting for critical illness, patients in the postintervention group had 17.7-fold higher odds (CI 1.9–162.6) of receiving definitive ceftriaxone or piperacillin-tazobactam (PTZ) compared to the preintervention group. No patients required retreatment for the same organism initially cultured, and neither group had ceftriaxone or PTZ resistance documented within 30 days posttreatment completion. Conclusion: The microbiology comment-based antimicrobial stewardship intervention led to increased ceftriaxone and PTZ prescribing for low-risk AmpC-producing Enterobacterales bloodstream infections compared to carbapenems, without affecting patient outcomes and increasing resistance rates.
- 29 October 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e355
Open AccessReducing carbapenem use for low-risk AmpC-producing Enterobacterales: impact of a microbiology comment-based stewardship initiative
Background: AmpC B-lactamases cause resistance to broad-spectrum B-lactams with variable expression dependent on bacterial species. Practice remains heterogenous regarding treatment of infections caused by AmpC organisms. This study aimed to assess the impact of a microbiology comment-based stewardship intervention on the definitive treatment of low-risk AmpC-producing Enterobacterales bacteremia. Methods: This was a pre- and posttest quality improvement study conducted at Island Health Authority. A stewardship intervention involving amendment of a microbiology report comment regarding inducible resistance was implemented on February 13, 2023. Patients aged 18 and older with blood cultures growing low-risk AmpC-producing organisms were included. The primary end point of proportion of patients receiving ceftriaxone or piperacillin-tazobactam was compared between pre- (June 2021 to February 2023) and postintervention periods (February 2023 to October 2024). Secondary end points included clinical outcomes, ceftriaxone/piperacilin-tazobactam resistance rates, and C. difficile infection. Results: A total of 56 patients were included (25 preintervention and 31 postintervention). Definitive ceftriaxone/pipercillin-tazobactam antibiotic therapy was prescribed more frequently postintervention compared to preintervention (45.8% vs 5.0%, P < .001). After adjusting for critical illness, patients in the postintervention group had 17.7-fold higher odds (CI 1.9–162.6) of receiving definitive ceftriaxone or piperacillin-tazobactam (PTZ) compared to the preintervention group. No patients required retreatment for the same organism initially cultured, and neither group had ceftriaxone or PTZ resistance documented within 30 days posttreatment completion. Conclusion: The microbiology comment-based antimicrobial stewardship intervention led to increased ceftriaxone and PTZ prescribing for low-risk AmpC-producing Enterobacterales bloodstream infections compared to carbapenems, without affecting patient outcomes and increasing resistance rates.
- 16 February 2026
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (3) , 1714-1723
Proteomic Adaptations of Escherichia coli in Urinary Tract Infection Patients
Urinary tract infections (UTIs) are among the most prevalent bacterial infections worldwide, with Escherichia coli responsible for the majority of cases. While much of what is known about E. coli physiology comes from laboratory culture, this paradigm overlooks the critical influence of the unique host environment on bacterial adaptation and pathogenesis. Here, we analyzed the E. coli proteome directly from the urine of five UTI-positive patients and compared it to their respective isolates after a single in vitro passage. The comparison revealed profound proteomic changes; notably, 37 proteins consistently expressed across all patient-derived samples were uniformly absent postculture. Functional analysis of the host-adapted E. coli proteome versus after a single laboratory passage (i.e., culture) points to key roles in nutrient acquisition, virulence, stress tolerance, and host interaction, highlighting adaptive features that are lost during culture. Among these were outer membrane transporters such as FepA, CirA, and YfiB, surface-exposed proteins with diagnostic and vaccine potential, and metabolic or stress-response enzymes such as SodA, NirB, MetE, and IlvA, which represent attractive drug targets due to their essential in vivo roles and absence in humans. Our findings demonstrate the value of profiling pathogens taken directly from the host environment, revealing proteins that may serve as novel biomarkers or therapeutic targets for UTIs.
- 16 February 2026
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (3) , 1714-1723
Proteomic Adaptations of Escherichia coli in Urinary Tract Infection Patients
Urinary tract infections (UTIs) are among the most prevalent bacterial infections worldwide, with Escherichia coli responsible for the majority of cases. While much of what is known about E. coli physiology comes from laboratory culture, this paradigm overlooks the critical influence of the unique host environment on bacterial adaptation and pathogenesis. Here, we analyzed the E. coli proteome directly from the urine of five UTI-positive patients and compared it to their respective isolates after a single in vitro passage. The comparison revealed profound proteomic changes; notably, 37 proteins consistently expressed across all patient-derived samples were uniformly absent postculture. Functional analysis of the host-adapted E. coli proteome versus after a single laboratory passage (i.e., culture) points to key roles in nutrient acquisition, virulence, stress tolerance, and host interaction, highlighting adaptive features that are lost during culture. Among these were outer membrane transporters such as FepA, CirA, and YfiB, surface-exposed proteins with diagnostic and vaccine potential, and metabolic or stress-response enzymes such as SodA, NirB, MetE, and IlvA, which represent attractive drug targets due to their essential in vivo roles and absence in humans. Our findings demonstrate the value of profiling pathogens taken directly from the host environment, revealing proteins that may serve as novel biomarkers or therapeutic targets for UTIs.